Literature DB >> 23066347

Second European post-chicago melanoma meeting 2012.

Walter Alexander.   

Abstract

Entities:  

Year:  2012        PMID： 23066347      PMCID： PMC3462606     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  5 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.

Authors:  Howard L Kaufman; Steven D Bines
Journal:  Future Oncol       Date:  2010-06       Impact factor: 3.404

3.  Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.

Authors:  Lawrence E Flaherty; Megan Othus; Michael B Atkins; Ralph J Tuthill; John A Thompson; John T Vetto; Frank G Haluska; Alberto S Pappo; Jeffrey A Sosman; Bruce G Redman; James Moon; Antoni Ribas; John M Kirkwood; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

4.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

Authors:  P B Chapman; L H Einhorn; M L Meyers; S Saxman; A N Destro; K S Panageas; C B Begg; S S Agarwala; L M Schuchter; M S Ernstoff; A N Houghton; J M Kirkwood
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Authors:  Axel Hauschild; Sanjiv S Agarwala; Uwe Trefzer; David Hogg; Caroline Robert; Peter Hersey; Alexander Eggermont; Stephan Grabbe; Rene Gonzalez; Jens Gille; Christian Peschel; Dirk Schadendorf; Claus Garbe; Steven O'Day; Adil Daud; J Michael White; Chenghua Xia; Kiran Patel; John M Kirkwood; Ulrich Keilholz
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.